| Not Yet Recruiting | Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Sup NCT07489573 | Novartis Pharmaceuticals | Phase 4 |
| Recruiting | The Safety and Efficacy of Roflumilast Foam in HS NCT07263230 | Beth Israel Deaconess Medical Center | Phase 2 |
| Not Yet Recruiting | Radiotherapy for Refractory Hidradenitis Suppurativa NCT07414550 | Thomas Jefferson University | N/A |
| Recruiting | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidr NCT07213973 | Incyte Corporation | Phase 2 |
| Not Yet Recruiting | MAIT Cells in Hidradenitis Suppurativa NCT07388446 | Hospices Civils de Lyon | N/A |
| Recruiting | A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa NCT07384975 | Navigator Medicines, Inc. | Phase 2 |
| Recruiting | Pelashield™ PainGuard™ vs Restrata® in HS Surgery NCT07316192 | Rutgers, The State University of New Jersey | N/A |
| Not Yet Recruiting | Real-World Study on the Burden of Hidradenitis Suppurativa NCT07323303 | PeriPharm | — |
| Not Yet Recruiting | Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa NCT06960447 | Geisinger Clinic | N/A |
| Not Yet Recruiting | Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS NCT07261072 | Peking Union Medical College | Phase 4 |
| Not Yet Recruiting | Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa NCT07244510 | Sinocelltech Ltd. | Phase 2 |
| Recruiting | A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa NCT07287644 | Bluefin Biomedicine, Inc. | Phase 2 / Phase 3 |
| Recruiting | A Study With CIT-013 in HS Patients NCT06993233 | Citryll BV | Phase 2 |
| Recruiting | 1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa) NCT07155239 | Wynn Medical Center | Phase 1 |
| Not Yet Recruiting | Neutralizing Interferon Type 1 in Hidradenitis Suppurativa NCT07067099 | Centre Hospitalier Universitaire de Besancon | Phase 1 |
| Recruiting | SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) NCT07021495 | Leiden University Medical Center | — |
| Recruiting | A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Reg NCT07123038 | Sonoma Biotherapeutics, Inc. | — |
| Recruiting | Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa NCT07109765 | Peking Union Medical College | — |
| Recruiting | Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense NCT06993610 | Zura Bio Inc | Phase 2 |
| Not Yet Recruiting | A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese A NCT06932003 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Mod NCT06946641 | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 |
| Recruiting | Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinic NCT06785779 | Novartis Pharmaceuticals | — |
| Recruiting | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib NCT06855498 | Incyte Corporation | Phase 3 |
| Completed | Molecular Evaluation of TAAR1 and JAK/STAT Pathway in Hidradenitis Suppurativa NCT07278011 | Trakya University | — |
| Withdrawn | Botulinum Toxin-A for Hidradenitis Suppurativa NCT06237465 | Yale University | Phase 4 |
| Recruiting | Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1% NCT06645821 | Virginia Clinical Research, Inc. | EARLY_Phase 1 |
| Completed | Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions. NCT07428941 | AI Labs Group S.L | — |
| Completed | Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin NCT07428915 | AI Labs Group S.L | — |
| Terminated | A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradeniti NCT06241573 | Boehringer Ingelheim | Phase 2 / Phase 3 |
| Active Not Recruiting | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe NCT06212999 | Incyte Corporation | Phase 3 |
| Completed | The Impact of Untreated Depression and Anxiety Among Patients With Skin Diseases in Jeddah, Saudi Arabia. NCT07046039 | King Abdulaziz University | — |
| Unknown | Autophagy Dysfunction in Hidradenitis Suppurativa NCT05723757 | Association pour la Recherche Clinique et Immunologique | N/A |
| Completed | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Seve NCT05620836 | Incyte Corporation | Phase 3 |
| Unknown | The Role of Host-microbiota Interplay in Hidradenitis Suppurativa Pathogenesis NCT05735925 | Association pour la Recherche Clinique et Immunologique | N/A |
| Completed | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Seve NCT05620823 | Incyte Corporation | Phase 3 |
| Completed | Hidradenitis Suppurativa Wound Care NCT04354012 | Wake Forest University Health Sciences | Phase 2 |
| Completed | A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidraden NCT04430855 | AbbVie | Phase 2 |
| Recruiting | Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa NCT06926192 | Peking Union Medical College | — |
| Completed | Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Supp NCT03894956 | AbbVie | — |
| Completed | Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) NCT03487276 | InflaRx GmbH | Phase 2 |
| Completed | Chronic Inflammatory Disease, Lifestyle and Treatment Response NCT03173144 | University of Southern Denmark | — |
| Completed | Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects NCT03001115 | AbbVie | — |
| Completed | Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness NCT02896920 | AbbVie | — |
| Completed | Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically NCT02808975 | AbbVie | Phase 4 |
| Completed | Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa NCT01468207 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Completed | Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa NCT01468233 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Available | Managed Access Programs for AIN457, Secukinumab NCT05583604 | Novartis Pharmaceuticals | — |